DermTech, Inc. (DMTK)
DermTech, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $0.09, down 11.32% on the session, giving a market capitalisation of $3.3M. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -659.6%. Its beta of 2.42 implies it has historically moved more than the broad market.
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
DermTech, Inc. is most often compared with the following Healthcare names: